Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo

Journal of Allergy and Clinical Immunology(2025)10.1016/j.jaci.2025.05.028Source: DataRank Database

High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo is a research paper published in Journal of Allergy and Clinical Immunology (2025). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.83)OA: hybridTopics (46)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Pascal Guntern ORCID,Luke F. Pennington ORCID,Robin van Brummelen ORCID,Theodore S. Jardetzky ORCID,Alexander Eggel ORCID

Live enrichment

PubMed:41081658 OpenAlex:https://openalex.org/W4415116655

National Institutes of Health

Grant: R01AI115469

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Grant: 310030_219361

Swiss National Science Foundation

Grant: 219361

Multifunctional IgE inhibitors: Deciphering their therapeutic modes-of-action in allergic disease

FWCI

1.83

Citation Percentile

0.9%

Citation Trend

2026

hybridLicense: cc-by

journalhttps://www.jacionline.org/article/S0091-6749(25)00623-2/pdf

publisherhttps://www.jacionline.org/article/S0091-6749(25)00623-2/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0091674925006232?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0091674925006232?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jaci.2025.05.028

Fields of Study

Mast cells and histamineMonoclonal and Polyclonal Antibodies ResearchFood Allergy and Anaphylaxis Research03 medical and health sciences0302 clinical medicineOmalizumabAnimalsAnaphylaxisImmunoglobulin EHumansMiceReceptors, IgEAnti-Allergic AgentsAntibody AffinityFemaleMast Cells

MeSH Terms

OmalizumabAnaphylaxisAnimalsAntibody AffinityFemaleHumansImmunoglobulin EMast CellsReceptors, IgEAnti-Allergic AgentsMice

Keywords

PotencyIn vivoOmalizumabAnaphylaxisBlockadeReceptors, IgEAntibody Affinitymast cellsImmunoglobulin Ereceptor-ligand disruptionanti-IgE antibodypassive systemic anaphylaxisMiceAnti-Allergic AgentsAnimalsHumansFemaleIgEbasophils